LCM
IBRX icon

Landscape Capital Management’s ImmunityBio IBRX Stock Holding History

Landscape Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11,670
Closed -$71K – 946
2021
Q4 		$71K Buy
+11,670
New +$87.7K 0.01% 808

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Landscape Capital Management's IBRX Position: Q1 2022 in Review

Landscape Capital Management sold out of ImmunityBio (IBRX) in Q1 2022, closing a stake of 11,670 shares — an estimated $71K sold.

Landscape Capital Management first reported a position in IBRX in Q4 2021 and held it in 1 quarter. The position peaked at $71K in Q4 2021. 149 funds tracked by Wall St. Rank hold IBRX as of Q1 2022.

  • Landscape Capital Management reported no remaining ImmunityBio position as of Q1 2022 after selling out during the quarter.
  • Landscape Capital Management sold 11,670 ImmunityBio shares in Q1 2022, an estimated $71K.
  • Landscape Capital Management first reported a position in ImmunityBio in Q4 2021 and held it in 1 quarter.
  • Landscape Capital Management's ImmunityBio position peaked at $71K in Q4 2021.
  • 149 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2022.

Based on Landscape Capital Management's 13F filing for Q1 2022, filed 11 May 2022.